Among them, more research has been conducted on the anti-cisplatin effect of GAST (Rao et al., 2017), and GNRH1 and STC1 can activate the c-Jun N-terminal kinase (JNK) pathway to facilitate tumor development (Lu et al., 2015; Pan et al., 2017). Here, STC1 is linked to neoplasm.